Devonian Health Group Reports Second Quarter 2025 Financial Results
PRESS RELEASE For immediate release Devonian Health Group Reports Second Quarter 2025 Financial Results Second quarter revenue increased 275% year over year Second quarter net loss of $0.001 per share Debt repaid in full Québec, QUÉBEC, April 15, 2025 – Devonian...
Devonian Health Group Reports Cease Trade Order
PRESS RELEASE For immediate release Devonian Health Group Reports Cease Trade Order QUEBEC CITY--(BUSINESS WIRE)--April 14, 2025--Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), announces that the Autorité des Marchés Financiers...
Devonian Reports Delay of Financial Reporting
PRESS RELEASE For immediate release Devonian Reports Delay of Financial Reporting QUÉBEC, April 1st, 2025 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to...
Devonian Reports Results of its Annual General and Special Meeting of Shareholders
PRESS RELEASE For immediate release Devonian Reports Results of its Annual General and Special Meeting of Shareholders Not for distribution to United States newswire services or for dissemination in the United States QUEBEC, March 24, 2025 – Devonian Health Group Inc....
Devonian Announces the Filing of a New Patent Application Relating to the Use of Thykamine™ as an antifibrotic agent
QUÉBEC, Québec, February 19, 2025 – Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, announces the filing of a new patent application...
DEVONIAN ANNOUNCES POSITIVE IN VIVO RESULTS OF THYKAMINE™ ON GENE EXPRESSION ASSOCIATED WITH FIBROSIS
Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, today announced positive results from a gene analysis conducted as part of in vivo study in STAM™ mouse model.
Devonian Announces the Filing of a New Provisional Patent Application Relating to the Use of Thykamine™ for treating Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Devonian Announces the Filing of a New Provisional Patent Application Relating to the Use of Thykamine™ for treating Metabolic Dysfunction-Associated Steatohepatitis (MASH) QUÉBEC, Québec, February 13, 2025 – Devonian Health Group Inc. (“Devonian” or the “Company”)...
DEVONIAN REPORTS POSITIVE RESULTS IN MASH LIVER STUDY
DEVONIAN REPORTS POSITIVE RESULTS IN MASH LIVER STUDY Positive results from the STAM mouse model in vivo study attributing Thykamine™ with anti-MASH and anti-fibrosis effects in liver Compelling results compared to Resmetirom, the first FDA approved drug for...
DEVONIAN REPORTS DISTRIBUTION AGREEMENT TERMINATION
PRESS RELEASE For immediate release QUEBEC, Québec, February 7, 2025 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, today announced...
DEVONIAN HEALTH GROUP INC. REPORTS SUPERIOR ANTI-INFLAMMATORY POTENCY OF THYKAMINE™ IN COMPARATIVE IN VITRO STUDY
PRESS RELEASE For immediate release In vitro study demonstrated superior potency of Thykamine™ against various corticosteroids and a phosphodiesterase inhibitor Supports the clinical efficacy results of Thykamine™ in previous and ongoing studies in the treatment of...